Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMA910 in advanced colorectal cancer
NCT00785122Phase 2Completed
- Sponsor
- Immatics
- Start
- Jun 2008
- Primary completion
- Jan 2011
- Modality
- Peptides, Vaccines & Immunotherapeutics
- Countries
- 9
01
Overview
Phase 2, open-label trial of IMA910 in colorectal carcinoma (CRC) (2 arms), sponsored by Immatics. Primary endpoints: Disease Control Rate at 27 weeks and Safety assessment. Started Jun 2008; status: completed.
02
Drugs
IMA910
03
Conditions
colorectal carcinoma (CRC)
Beyond the preview
Go deeper on NCT00785122.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00785122.